Bernard A Fox

14PUBLICATIONS
67CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 13, 2026
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

|Apr 02, 2026
Bright side of the dark genome: antigens for next-gen cancer vaccines.

Xiao-Song Wang, Bernard A Fox

|Dec 21, 2025
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).

Sam Sater, Carlo B Bifulco, Jaime Rodriguez-Canales

|Jul 17, 2025
The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy.

Robert Saddawi-Konefka, Riyam Al Msari, Shiqi Tang

|May 13, 2025
Asia's emergence in cancer immunotherapy: challenges and opportunities.

Yan Li, Joe Yeong, Bernard A Fox

|Nov 18, 2024
IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells.

Olivier Fesneau, Kimberly A Samson, Wesley Rosales

Pageof 3

Frequent Collaborators

6 joint publications

Shawn M Jensen

2 joint publications

Rieneke van de Ven

2 joint publications

Rom S Leidner

2 joint publications

David B Page